Viral Vector Vaccines

A viral vector vaccine uses a harmless or attenuated virus — most commonly an adenovirus — engineered to carry the gene for a target pathogen's antigen. After vaccination, the vector delivers that gene into the recipient's cells, which then synthesize the antigen and present it to the immune system. Because the antigen is made inside the body much as in a real infection, this platform efficiently elicits both antibody and cytotoxic T-cell responses, and it was used in several COVID-19 and Ebola vaccines.

Definition

A viral vector vaccine is a recombinant, replication-deficient or attenuated virus engineered to deliver the gene encoding a target antigen into host cells, so that the cells express the antigen and induce protective immunity without the target pathogen being present.

Scope

This topic covers how viral vectors are designed and chosen, why endogenous antigen expression drives strong cellular and humoral immunity, and the platform's key challenge of pre-existing or vector-directed immunity. It is a methodological reference and does not provide schedules or eligibility advice.

Core questions

• How is a viral vector engineered to deliver an antigen gene safely?
• Why does endogenous antigen expression elicit strong T-cell as well as antibody responses?
• How does pre-existing immunity to the vector limit effectiveness, and how is it mitigated?

Key concepts

• Recombinant viral vector
• Adenovirus and other vector backbones
• Replication-deficient design
• Endogenous antigen expression
• Cytotoxic T-cell induction
• Anti-vector (pre-existing) immunity
• Prime-boost with heterologous vectors

Mechanisms

The vector virus is modified so that it carries the antigen-encoding gene and, in most platforms, cannot replicate productively. On vaccination it enters host cells and the antigen is synthesized intracellularly, entering antigen-presentation pathways that prime cytotoxic T cells while the expressed protein also drives antibody responses, yielding broad immunity. The platform's main limitation is immunity directed against the vector itself: pre-existing antibodies to a common vector (or those generated by a first dose) can blunt the response, which is why rare human or animal-derived adenoviruses are used and why heterologous prime-boost regimens, pairing different vectors, are employed. Viral-vector vaccines were central to the response to COVID-19 (for example ChAdOx1 and Ad26.COV2.S) and to Ebola.

Clinical relevance

Viral vector vaccines provide a rapidly adaptable platform that elicits strong cellular and humoral immunity and proved valuable against emerging epidemic pathogens. Understanding the platform clarifies why such vaccines are potent yet can be affected by immunity to the vector. This entry describes the science of the platform and is not a source of individual vaccination advice.

Epidemiology

Viral-vector vaccines were deployed at large scale against COVID-19 and used in outbreak settings such as Ebola, demonstrating the platform's suitability for rapid response; vector-directed immunity remains a design consideration that shapes vector choice and dosing strategy.

History

The use of viruses as gene-delivery vehicles for vaccination developed from gene-therapy and recombinant-virus research in the late twentieth and early twenty-first centuries, reviewed by Draper and Heeney in 2009. The platform reached large-scale public use during the COVID-19 pandemic with adenovirus-vectored vaccines validated in randomized trials such as those of Voysey and colleagues (ChAdOx1) and Sadoff and colleagues (Ad26.COV2.S).

Key figures

• Simon Draper
• Florian Krammer

Seminal works

• draper-2009
• voysey-2021
• sadoff-2021

Frequently asked questions

How does a viral vector vaccine work?

A harmless, usually replication-deficient virus carries the gene for the target antigen into the recipient's cells, which then make the antigen; because the antigen is produced inside cells, the platform induces both antibody and cytotoxic T-cell responses.

What is anti-vector immunity and why does it matter?

It is an immune response against the carrier virus itself, from prior exposure or an earlier dose, which can reduce how well the vector delivers its gene; designers address it by using uncommon vectors and heterologous prime-boost combinations.